However, it may also reflect the fact that there are currently no specific requirements regarding the limit of detection (LOD) for the methods used for KRAS mutation testing, in spite of recent evidence indicating that mCRC patient tumors with as few as 1% KRAS mutated cancer cells fail to respond to anti-EGFR therapies [17]. Here, KRAS is linked to cancer.